Geron Corporation

GERN·NasdaqGS·Healthcare
Compare
1.0800+0.1500 (+16.13%)today
At close: Nov 4, 4:00 PM EST · May be delayed up to 15 min · USD
Pre-market1.0600−0.0200 (−1.85%)

Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.

Key statistics

Previous close0.9300
Open1.0100
Day range0.96141.0800
52-week range0.84002.0100
Off day high0.00%
Off 52-week high−46.27%
Volume26.87M
Avg. volume (3M)12.08M
Market cap693.87M
EPS (TTM)-0.0800
Forward P/E27.00
P/E ratio (TTM)—
Dividend yield—
Beta (5Y)0.61
Shares outstanding642.47M
Short interest11.62% of float
Earnings dateNov 4, 2026
Analyst target3.6250
Profit margin−33.05%

Against its peers

Compare in full ›
GERN KROS SLDB RIGL SNDX ZVRA
Market cap 693.87M 214.73M 699.11M 958.09M 940.80M 663.32M
P/E (TTM) — — — 3.0 — 9.2
Forward P/E 27.0 -1.6 -3.8 10.4 -14.4 10.4
Price/book 3.1 0.8 2.9 2.2 -54.7 4.1
Dividend yield — — — — — —
1-year change −14.68% −30.80% +59.80% +29.09% −5.36% +1.89%
Today +16.13% 0.00% +3.82% +4.97% −26.87% +8.87%

The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.

Latest news

All GERN news ›
Markets Daily·

Reviewing Geron (NASDAQ:GERN) and MDxHealth (NASDAQ:MDXH)

Posted by Mitch Edgeman on Nov 3rd, 2026 Geron (NASDAQ:GERN – Get Free Report) and MDxHealth (NASDAQ:MDXH – Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will compare the two businesses…

Seeking Alpha·Positive

Geron: Opportunity Builds Even As Struggles Continue

Geron achieved FDA approval for RYTELO in June 2024, targeting lower-risk myelodysplastic syndromes. Read what makes GERN stock a compelling Buy. - Geron achieved FDA approval for RYTELO (imetelstat) in June 2024, targeting lower-risk…

@SantaClaraUniv·Negative

What Really Went Wrong with Enron?

I am going to concentrate on the third kind of explanation for what went wrong with Enron-the systemic explanations…. Second, a private company like Enron currently hires and pays its own auditors. This again is a conflict of interest…

Stevens Point·Negative

Geron discontinues late-stage trial of blood cancer drug

Oct 28 (Reuters) – Geron said on Wednesday it would discontinue a ​late-stage trial testing ‌its treatment for patients with a form of rare blood cancer. The drug, branded ‌as ​Rytelo, was ⁠being evaluated as ⁠a treatment for…

Defense World·Positive

Contrasting Absci (NASDAQ:ABSI) & Geron (NASDAQ:GERN)

Posted by Defense World Staff on Oct 25th, 2026 Absci (NASDAQ:ABSI – Get Free Report) and Geron (NASDAQ:GERN – Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will compare the two businesses…

From the 4Search news index, newest first.

In the news

41mentions in 30 days
17with it in the headline
Negativesentiment

Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 41 articles, not a forecast.

Market data is provided for information only and comes from free public sources. Prices may be delayed up to 15 minutes; data may be incomplete or inaccurate. Nothing on this page is investment advice or a recommendation to buy or sell any security. News and coverage analytics are drawn from the 4SEARCH.business index. Terms of use. How to use Finance